COMMUNIQUÉS West-GlobeNewswire

EvergreenHealth receives transformative $100M gift from Dean Weidner
28/09/2026
The gift enables EvergreenHealth to accelerate long-term planning for expanded access and increased capacity to deliver high-quality care to the community KIRKLAND, Wash., Sept. 28, 2026 (GLOBE NEWSWIRE) -- [...]
Fetal surgeon Payam Saadai, MD, to join Rady Children’s Health Orange County
28/09/2026
Recruitment will advance specialized fetal care for families across Southern California ORANGE, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Rady Children’s Health Orange County (Rady Children’s), formerly CHOC, announced [...]
Une nouvelle analyse modélisée renforce le potentiel de TECVAYLI®▼ (teclistamab) associé au daratumumab pour redéfinir les perspectives de survie à long terme dans le myélome multiple en rechute/réfractaire dans les premières lignes de traitement
28/09/2026
Selon l’analyse, environ 87 pour cent des patients traités par TECVAYLI ® ▼ associé au daratumumab dès la deuxième ligne pourraient présenter un risque de mortalité comparable à celui de la population générale 1 Une [...]
GENFIT : Résultats financiers du premier semestre 2026 et point sur les activités de la Société
28/09/2026
Résultats financiers marquants : Trésorerie et équivalents de trésorerie s’élevant à 113,8 millions d’euros au 30 juin 2026; devant permettre à la Société de financer ses activités au-delà de la fin de l’année 2028 [...]
GENFIT Reports First-Half 2026 Financial Results and Provides Corporate Update
28/09/2026
Financial Highlights Cash and cash equivalents totaled €113.8 million as of June 30, 2026; expected to fund the Company beyond the end of 2028 €21.1 million in revenues as of June 30, 2026, including €21.0 million in [...]
ORYZON Receives European Medicines Agency Approval to Initiate the HOPE-2 Phase II Study of Vafidemstat for the Treatment of Phelan-McDermid Syndrome (PMS)
28/09/2026
PMS is a severely disabling genetic disorder related to autism U.S. prevalence is estimated at approximately 1 in 7,300 people HOPE-2 is partially funded through Oryzon’s VANDAM project under Med4Cure, an Important [...]
Callio Therapeutics Appoints Chris Hassig, PhD, as Chief Scientific Officer
28/09/2026
Industry veteran brings more than two decades of oncology drug discovery leadership to advance Callio's dual-payload ADC pipeline SAN DIEGO and SEATTLE and SINGAPORE, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Callio [...]
NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes
28/09/2026
Following successful FDA Pre-IND meeting, NewcelX advances IND-enabling activities for NCEL-101 ZURICH, Sept. 28, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL), a regenerative medicine company developing stem- [...]
GuideAI Health Corp. and vRad Renew Data Exclusivity Agreement to Develop AI Models for the Detection and Characterization of Multiple Vascular Diseases
28/09/2026
Company holds exclusive access to imaging data from 2,100+ U.S. hospitals through its ongoing data partnership with vRad, the largest teleradiology provider in the United States BOSTON, Sept. 28, 2026 (GLOBE NEWSWIRE [...]
ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer
28/09/2026
Achieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for control, with response rates increasing to 63.6% versus 23.1% among patients with high CD47 expression and retained HER2- [...]
4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME
28/09/2026
4D-150 is advancing into Phase 3 development for DME, a second multi-billion-dollar retinal disease market with significant unmet need First patients have been enrolled in 4SIGHT global Phase 3 trial (N=514) evaluating [...]
Route 92 Medical Announces U.S. FDA Clearance for the FreeClimb® 46 Catheter with Tenzing® 4
28/09/2026
Expands Company’s Portfolio of Advanced Neurovascular Catheters to Support Treatment in Smaller and More Distal Anatomies WEST JORDAN, Utah, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held [...]
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
28/09/2026
Initial data expected in the first half of 2027 LEXINGTON, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing [...]
Curonix Announces Published PNS IMPACT Clinical Study Showing Freedom® Peripheral Nerve Stimulator (PNS) System is Associated with Reductions in Pain Scores, Opioid Use and Overall Patient Burden
28/09/2026
POMPANO BEACH, Fla., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Curonix LLC, a leading medical technology company dedicated to relieving chronic pain, today announced the publication of a milestone study, Peripheral Nerve [...]
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
28/09/2026
DURHAM, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, [...]
Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research
28/09/2026
- Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib - New proteomics and cell line capabilities will broaden Allarity’s research capabilities to enable external partnerships [...]
Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection
28/09/2026
New U.S. patent expands intellectual property foundation for DARE-HPV, a potential first-in-category treatment targeting persistent high-risk HPV infection DARE-HPV Phase 2 study underway with topline results expected [...]
Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers
28/09/2026
Translational research demonstrates that SIL204 utilizes native serum lipids to facilitate intracellular delivery and robust KRAS oncogene knockdown Findings validate that physiological lipoprotein levels are sufficient [...]
Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026
28/09/2026
SEATTLE and VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and [...]

Pages